PRLD
Prelude Therapeutics Incorporated
Biotechnology · Healthcare · United States
3.88
close · 2026-10-30
value
16
cheaper than peers16
quality
21
stronger fundamentals21
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.99× | 54 |
| price to sales | 18.52× | 39 |
| cash flow yield, latest year | -18.2% | 38 |
| earnings yield, latest year | -33.2% | 32 |
| earnings yield, 2 years ago | -52.1% | 29 |
| earnings yield, 1 year ago | -43.3% | 29 |
| earnings yield, 3 years ago | -62.9% | 27 |
| cash flow yield, 2 years ago | -35.7% | 25 |
| cash flow yield, 3 years ago | -28.0% | 24 |
| cash flow yield, 1 year ago | -33.5% | 23 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -309.5% | 41 |
| debt to equity | 29.4% | 39 |
| return on equity | -95.2% | 27 |
3 of 4 measures available
Facts
| market cap | $310M |
| free cash flow | -$17.9M |
| employees | 79 |
| first trade | 2020-09-25 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-11 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.29 | -1.68 | -2.02 | -2.44 |
| free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M |
| net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M |
| revenue | $12.1M | $7.0M | $0 | $0 |